Recently, the company has obtained an industrial and commercial license in Pujiang Town, Minhang District, and is headquartered in the advanced manufacturing industrial base of Pujiang International Science and Technology City, Lingang, with R&D centers in Shanghai and Beijing and GMP production centers in Suzhou Industrial Park.
Inplus Biotech is a technology-based platform company focusing on the wide application of proteins in biomedicine and other major livelihood fields. As a manufacturer of high-end protein raw materials (antigens, antibodies and enzymes) and quality control detection kits, it has been established for 3 years and has completed three rounds of financing led by CDH Investment, Gaorong Capital, CMB International and other leading investment institutions.
Inplus Biotech has successively obtained municipal high-tech enterprises, technology-based small and medium-sized enterprises, specialized and special new small and medium-sized enterprises and ISO9001 certification, and has been selected into the 2023 Future Medical VB100 Top 100 and CHC-CITIC ** 2022 Medical and Health Most Valuable Investment Enterprise List, and has developed nearly 100 kinds of detection reagent products used in core high-end raw materials covering new drug research and development, diagnosis, vaccines, cells and other biomedical fields, as well as the quality control needs of sexual biological agents. Innovative pharmaceutical companies, listed diagnostic companies and the Academy of Sciences empower and provide products comparable to imports.
*: Minhang today.